BIOMAT Database Logo BIOMAT Database Logo

Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver. 2019

Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited , Fujisawa , Kanagawa , Japan.

1. The prediction of human pharmacokinetic (PK) parameters is an important theme to select drug candidates from preclinical studies. It is essential to improve the prediction accuracy of compound half-life (t1/2) in humans. In this study, the predictability of t1/2 in humans using PXB mice®, chimeric mice with humanised liver, was assessed using 14 compounds showing long t1/2 in humans. 2. After intravenous administration of the compounds to PXB mice, the plasma concentration-time profiles were fitted using one- or two-compartment models and the human clearance (CLt) and distribution volume (Vdss) were predicted from single-species scaling. Using the obtained parameters, the t1/2 in humans was predicted. Using PXB mice, the predicted t1/2 values of 71.4% of the compounds were within two-fold of the actual values. Meanwhile, based on predictions using SCID mice, the host strain of the PXB mice, only 7.1% of tested compounds were within two-fold. 3. In conclusion, we demonstrated the novel utility of PXB mice for human PK predictions of compounds having long t1/2 in humans.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D010599 Pharmacokinetics Dynamic and kinetic mechanisms of exogenous chemical DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology. ADME,ADME-Tox,ADMET,Absorption, Distribution, Metabolism, Elimination, and Toxicology,Absorption, Distribution, Metabolism, and Elimination,Drug Kinetics,Kinetics, Drug,LADMER,Liberation, Absorption, Distribution, Metabolism, Elimination, and Response
D002678 Chimera An individual that contains cell populations derived from different zygotes. Hybrids,Chimeras,Hybrid
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016513 Mice, SCID Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice. SCID Mice,SCID-hu Mice,Severe Combined Immunodeficient Mice,Immunodeficient Mice, Severe Combined,Mouse, SCID,Mouse, SCID-hu,Mice, SCID-hu,Mouse, SCID hu,SCID Mouse,SCID hu Mice,SCID-hu Mouse
D022781 Hepatocytes The main structural component of the LIVER. They are specialized EPITHELIAL CELLS that are organized into interconnected plates called lobules. Hepatic Cells,Cell, Hepatic,Cells, Hepatic,Hepatic Cell,Hepatocyte

Related Publications

Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver.
April 2019, Xenobiotica; the fate of foreign compounds in biological systems,
Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
February 2012, Drug metabolism and disposition: the biological fate of chemicals,
Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers.
November 2012, Xenobiotica; the fate of foreign compounds in biological systems,
Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Prediction of human pharmacokinetics for low-clearance compounds using pharmacokinetic data from chimeric mice with humanized livers.
January 2022, Clinical and translational science,
Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Predictability of human pharmacokinetics of diisononyl phthalate (DINP) using chimeric mice with humanized liver.
November 2019, Xenobiotica; the fate of foreign compounds in biological systems,
Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver.
January 2009, Drug metabolism and pharmacokinetics,
Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Prediction of Human Disproportionate and Biliary Excreted Metabolites Using Chimeric Mice with Humanized Liver.
October 2020, Drug metabolism and disposition: the biological fate of chemicals,
Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Pharmacokinetics of long half-life antibacterials.
November 1979, The Journal of antimicrobial chemotherapy,
Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Quantitative Prediction of OATP-Mediated Disposition and Biliary Clearance Using Human Liver Chimeric Mice.
November 2023, The Journal of pharmacology and experimental therapeutics,
Maki Miyamoto, and Shinji Iwasaki, and Ikumi Chisaki, and Sayaka Nakagawa, and Nobuyuki Amano, and Yohei Kosugi, and Hideki Hirabayashi
Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver.
April 2023, Xenobiotica; the fate of foreign compounds in biological systems,
Copied contents to your clipboard!